Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

Tools

Item Type:	Letter
Title:	Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer
Creators Name:	Gupta, S., Strohbehn, I.A., Wang, Q., Hanna, P.E., Seethapathy, R., Prosek, J.M., Herrmann, S.M., Abudayyeh, A., Malik, A.B., Loew, S., Carlos, C.A., Chang, W.T., Beckerman, P., Mithani, Z., Shah, C.V., Renaghan, A., de Seigneux, S., Campedel, L., Kitchlu, A., Shin, D.S., Coppock, G., Lumlertgul, N., Garcia, P., Ortiz-Melo, D.I., Rashidi, A., Sprangers, B., Aggarwal, V., Benesova, K., Jhaveri, K.D., Cortazar, F.B., Weins, A., Zuo, Y., Mooradian, M.J., Reynolds, K.L., Leaf, D.E. and Sise, M.E.
Keywords:	Acute Kidney Injury, Antineoplastic Combined Chemotherapy Protocols, Humanized Monoclonal Antibodies, Lung Neoplasms
Source:	Kidney International
ISSN:	0085-2538
Publisher:	Nature Publishing Group
Volume:	102
Number:	4
Page Range:	930-935
Date:	October 2022
Additional Information:	Kai Schmidt-Ott is a member of the ICPi-AKI Consortium
Official Publication:	https://doi.org/10.1016/j.kint.2022.07.019
External Fulltext:	View full text on PubMed Central
PubMed:	View item in PubMed

Repository Staff Only: item control page